Linker Information
General Information of This Linker
| Linker ID |
LIN0EKLJX
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
DBCO-4,4 nnAA-B-Glucuronide-PEG12
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C74H106N6O26
|
|||||
| Isosmiles |
COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NC[C@H](NC(C(C1)CC21CN(C(CCCCC(N3C4=C(C#CC5=C(C=CC=C5)C3)C=CC=C4)=O)=O)C2)=O)C(NCCC(NCC6=CC(CO)=CC=C6O[C@H]7[C@H](O)[C@@H](O)[C@H](O)C(O7)C(O)=O)=O)=O)=O
|
|||||
| InChI |
InChI=1S/C74H106N6O26/c1-93-22-23-95-26-27-97-30-31-99-34-35-101-38-39-103-42-43-104-41-40-102-37-36-100-33-32-98-29-28-96-25-24-94-21-19-63(83)77-48-59(71(90)75-20-18-62(82)76-47-57-44-53(50-81)14-17-61(57)105-73-68(88)66(86)67(87)69(106-73)72(91)92)78-70(89)58-45-74(46-58)51-79(52-74)64(84)12-6-7-13-65(85)80-49-56-10-3-2-8-54(56)15-16-55-9-4-5-11-60(55)80/h2-5,8-11,14,17,44,58-59,66-69,73,81,86-88H,6-7,12-13,18-43,45-52H2,1H3,(H,75,90)(H,76,82)(H,77,83)(H,78,89)(H,91,92)/t59-,66-,67-,68+,69?,73+/m0/s1
|
|||||
| InChIKey |
TVSBWNFUFSILRC-OGPNZFDGSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1495.678
|
Polar area
|
404.46
|
||
|
Complexity
|
3099.575589
|
xlogp Value
|
0.1381
|
|||
|
Heavy Count
|
106
|
Rot Bonds
|
55
|
|||
|
Hbond acc
|
25
|
Hbond Donor
|
9
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
ZA202500202A D04-Y180F404/K42/E161-LP20 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.222 nM
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.
Click to Show/Hide
|
||||
| In Vitro Model | Embryonal carcinoma | Ntera-2 cells | CVCL_0034 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 10 nM | Negative ROR1 expression (ROR1-) | ||
| Method Description |
MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
References